Novo Nordisk introduces NovoCare® Pharmacy, lowering cost of all doses of FDA-approved Wegovy (semaglutide) to $499 per month and offering easy home

[StopCraving_12]

"As part of its ongoing efforts to ensure patients who need Wegovy® (semaglutide) injection 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg can access it, Novo Nordisk launched NovoCare® Pharmacy, a direct-to-patient delivery option that offers cash-paying patients all dose strengths of Wegovy® at a reduced cost of $499 per month."

Novo Nordisk introduces NovoCare® Pharmacy, lowering cost of all doses of FDA-approved Wegovy® (semaglutide) to $499 per month and offering easy home delivery for cash-paying patients

NovoCare® Pharmacy provides direct-to-patient, convenient home shipments of all dose strengths of Wegovy® at a reduced cost of $499 per month for cash-paying...

www.prnewswire.com

 

[indolent]

That's nice.

It's going off patent very soon, but they had every opportunity to do this seven years ago when they started selling it.

And they still have the opportunity to drop it below $150/month, which (AFAIK) has always been the retail unsubsidized price in other wealthy countries like France and Japan.

 

[DevynL90]

That's nice.

It's going off patent very soon, but they had every opportunity to do this seven years ago when they started selling it.

And they still have the opportunity to drop it below $150/month, which (AFAIK) has always been the retail unsubsidized price in other wealthy countries like France and Japan.

i believe they still have a long runway of exclusivity in the US though, right? isn't the patent expiration that's coming up for canada specifically?

 

[indolent]

i believe they still have a long runway of exclusivity in the US though, right? isn't the patent expiration that's coming up for canada specifically?

Correct. All global markets in 2026, when a true grey market (I consider our a black market) will develop because they used weasly extensions in the US to bring (current) expiration to 2032. And because $499 is more than $130.

Tirzepatide's exclusivity period runs out in the US in 2036, but I suspect they have extension tricks up their sleeve also